FIELD: immunology.
SUBSTANCE: present invention relates to immunology. Disclosed is an anti-ROBO4 antibody and antigen-binding fragment thereof. Also disclosed are: a polynucleotide encoding said antibody, a vector, a cell, and a method for producing an antibody or antigen-binding fragment thereof. In addition, pharmaceutical composition, a method and use of the antibody or antigen-binding fragment thereof for the prevention or treatment of an angiogenic disease are considered.
EFFECT: said antibody activates the downstream signal of ROBO4 and has a suppressive effect on migration induced by VEGF or bFGF, as well as an anti-angiogenic effect on in-vivo models.
30 cl, 55 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| NEW ANTIBODY TO TSLP-RECEPTOR OF HUMAN | 2014 |
|
RU2689528C2 |
| ANTI-CD3-ANTIBODY AND MOLECULE CONTAINING THIS ANTIBODY | 2017 |
|
RU2790326C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2663123C2 |
| QUICK METHOD OF CLONING AND EXPRESSION OF RELATED ANTIBODY VARIABLE REGION GENE SEGMENTS | 2012 |
|
RU2612910C2 |
| IL-17 ANTAGONIST ANTIBODIES | 2005 |
|
RU2426741C2 |
| NEW COMPLETELY HUMAN VAP-1 MONOCLONAL ANTIBODIES | 2008 |
|
RU2459832C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND PREVENTING CANCER | 2009 |
|
RU2533460C2 |
| THERAPEUTIC BINDING MOLECULES | 2002 |
|
RU2328506C2 |
